Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study


Akdag I., YILMAZ Y., Kahvecioglu S., BOLCA TOPAL N., ERCAN İ., Ersoy A., ...More

NEPHRON CLINICAL PRACTICE, vol.108, no.2, 2008 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 108 Issue: 2
  • Publication Date: 2008
  • Doi Number: 10.1159/000113526
  • Journal Name: NEPHRON CLINICAL PRACTICE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Keywords: end-stage renal disease, hemodialysis, cardiovascular disease, inflammation, malnutrition, mortality, HEMODIALYSIS-PATIENTS, NUTRITION, MARKERS

Abstract

Background/Aim: Mortality resulting from cardiovascular disease in patients with end-stage renal disease (ESRD) is high. In this study we sought to investigate the clinical value of the malnutrition-inflammation-atherosclerosis (MIA) syndrome for long-term prediction of cardiovascular mortality in patients treated with ESRD. Methods: A total of 42 ESRD patients on hemodialysis were enrolled. Inflammatory markers and nutritional parameters were determined. Carotid atherosclerosis was investigated by ultrasonographically evaluated carotid intima-media thickness (cIMT). Mortality was evaluated at a 5-year follow-up. Results: No correlation was evident between nutritional markers and inflammatory indexes. cIMT was inversely correlated with predialysis serum albumin. In the overall population of 42 patients, 11 (26.2%) died of cardiovascular causes during follow-up. Kaplan-Meier survival curves indicate that cIMT (>= 0.9 mm), C-reactive protein (CRP) (>1 mg/dl), and serum albumin (<3.5 g/dl) predict cardiovascular death in patients with ESRD. Conclusions: We have demonstrated that cIMT, CRP and serum albumin predict long-term mortality in ERSD patients. Our study suggests that further investigation of the MIA syndrome will provide insights into the susceptibility to CVD in this patient group. Copyright (C) 2008 S. Karger AG, Basel.